Day: August 14, 2025

Expands senior leadership team and board of directors to support next phase of growth ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, “We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management. Equally important, we have significantly strengthened our...

280% increase in quarterly revenue with a strong start in its energy services and edge computing businesses puts the Company on plan to achieve guidance of $28M to $30M for the full year JACKSONVILLE, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), a provider of adaptive, versatile and streamlined Edge Data Center (“EDC”) solutions and operational services for the deployment of “behind the meter” electrical power reported financial results for the second quarter (“Q2 2025”) ended June 30, 2025. In addition to the equivalent quarter revenue growth, consecutive quarterly revenue growth was more than 16% for a total of $10.7 million for the first six months, the highest revenue for that period in the Company’s history.Second Quarter 2025 and Recent Operational...

POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights:Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the healthcare sector Completed enrollment in a clinical trial evaluating BioREtain® Amnion Chorion for the treatment of diabetic foot ulcers, with a data readout expected in the fourth quarter 2025 Initiated expansion of the commercial organization including the hiring of direct representatives to access new sites of care Expanded the intellectual...

IRVINE, Ca., Aug. 14, 2025 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, climate resilience, energy transition and sustainable transportation, today announced financial results for the second quarter ended July 4, 2025. Second Quarter 2025 and Recent HighlightsReported revenue of $128 million, up 42% year over year, with $113 million coming from Shimmick Projects Reported gross margin of $8 million, as compared to gross margin of $(31) million during the second quarter of 2024, favorable 126% year over year Strong performance on Shimmick Projects contributed gross margin of $15 million, with Non-Core gross margin of $(7) million Reported selling, general and administrative expenses of $15 million, down 20% from the second quarter of 2024 as a result of the continued implementation...

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline,” said Willie Quinn, President and Chief Executive Officer. “We are now conducting a Phase 1 dose-escalation study for patients with gastric and gastroesophageal cancer in Australia, and will expand to other countries in the second...

Second Quarter Net Sales and Adjusted EBITDA Above Guidance Driven by 51% OEM GrowthPreferred Stock Exchange and Public Offering Strengthen Financial PositionGuides to Third Quarter Net Sales of Approximately $15.9 Million Second Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period)Net sales were $16.2 million, compared to $13.2 million, up 23.0%. OEM net sales were $10.1 million, compared to $6.7 million, up 50.6% Gross Margin was 28.3%, compared to 24.0%, up 430 basis points. Net Loss was $(7.0) million, compared to $(13.6) million. Adjusted EBITDA was $(2.2) million, compared to $(6.2) million.RENO, Nev., Aug. 14, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of Financial Results & Recent Progress:Total revenue for the second quarter of $15.7 million, down 5% year-over-year and up 15% quarter-over-quarterU.S. revenue up $0.4 million, or 5%, year-over-year driven by growth in cash systems sales of $1.0 million, or 23%, year-over-yearSecond quarter GAAP net loss of $11.7 million, compared to $19.9 million last year Second quarter Adjusted EBITDA loss of $8.8 million, compared to $4.1 million last year On April 10, 2025, the Company announced the closing of a registered direct offering priced at-the-market under Nasdaq rules for the...

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 vs. Second Quarter 2024 Financial SummaryTotal revenue for the quarter increased significantly to a record $1.4 million, compared to $0.3 million a year ago.Operating expenses were $5.9 million, compared to $3.6 million a year ago.Net loss was $4.5 million, or $0.33 per share, compared to a loss of $3.3 million, or $0.34 per share a year ago.Adjusted EBITDA Loss of $3.4 million (non-GAAP measure as defined below), compared with $2.5 million a year ago.Gross bARR (Booked Annual Recurring Revenue) of $2.2 million (non-GAAP measure as defined...